Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial

ObjectivesTo examine the long-term survival outcome of dabrafenib in combination with trametinib in Chinese patients with unresectable or metastatic acral/cutaneous melanoma with BRAF-V600 mutation and to explore potential predictors of effectiveness.MethodsThis was a long-term follow-up of Chinese...

Description complète

Détails bibliographiques

Auteurs principaux:	Lili Mao, Ya Ding, Xue Bai, Xinan Sheng, Jie Dai, Zhihong Chi, Chuanliang Cui, Yan Kong, Yun Fan, Yanjun Xu, Xuan Wang, Bixia Tang, Bin Lian, Xieqiao Yan, Siming Li, Li Zhou, Xiaoting Wei, Caili Li, Jun Guo, Xiaoshi Zhang, Lu Si
Format:	Artigo
Langue:	Inglês
Publié:	Frontiers Media S.A. 2021-08-01
Collection:	Frontiers in Oncology
Sujets:	melanoma dabrafenib trametinib BRAF acral melanoma
Accès en ligne:	https://www.frontiersin.org/articles/10.3389/fonc.2021.720044/full
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!